QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.019992v1 69/3/680    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Foucaud, M. Articles by Fourmy, D. Search for Related Content PubMed PubMed Citation Articles by Foucaud, M. Articles by Fourmy, D. Pubmed/NCBI databases Substance via MeSH

Partial Agonism, Neutral Antagonism, and Inverse Agonism at the Human Wild-Type and Constitutively Active Cholecystokinin-2 Receptors

Institut National de la Santé et de la Recherche Médicale, Unit 531, Institut Fédératif de Recherche, Toulouse, France; Université de Toulouse 3, Toulouse, France (M.F., I.G.T., I.L., C.E., M.D., C.S., D.F.); and Centre National de la Recherche Scientifique, Laboratoire de Chimie Théorique, Université de Nancy, Vandoeuvre, Nancy, France (B.M.)

Cholecystokinin receptor-2 (CCK2R) is a G protein receptor that regulates a number of physiological functions. Activation of CCK2R and/or expression of a constitutively active CCK2R variant may contribute to human diseases, including digestive cancers. Search for antagonists of the CCK2R has been an important challenge during the last few years, leading to discovery of a set of chemically distinct compounds. However, several early-discovered antagonists turned out to be partial agonists. In this context, we carried out pharmacological characterization of six CCK2R antagonists using COS-7 cells expressing the human CCK2R or a CCK2R mutant having a robust constitutive activity on inositol phosphates production, and we investigated the molecular mechanisms which, at a CCK2R binding site, account for these features. Results indicated that three compounds, 3R(+)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)urea (L365,260), 4-{[2-[[3-(lH-indol-3-yl)-2-methyl-1-oxo-2-[[[1.7.7-trimethyl-bicyclo[2.2.1]hept-2-yl)-oxy]carbonyl]amino]propyl]amino]-1-phenylethyl]amino-4-oxo-[lS-la.2[S^*(S^*)]4a]}-butanoate N-methyl-D-glucamine (PD135,158), and (R)-1-naphthalenepropanoic acid, b-[2-[[2-(8-azaspiro-[4.5]dec-8-ylcarbonyl)-4,6-dimethylphenyl]amino]-2-oxoethyl] (CR2945), were partial agonists; one molecule, 1-[(R)-2,3-dihydro-1-(2,3-dihydro-1-(2-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), was a neutral antagonist; and two compounds, N-(+)-[1-(adamant-1-ylmethyl)-2,4-dioxo-5-phenyl2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl]-N'-phenylurea (GV150,013X) and ([(N-[methoxy-3 phenyl] N-[N-methyl N-phenyl carbamoylmethyl], carbomoyl-methyl)-3 ureido]-3-phenyl)2-propionic acid (RPR101,048), were inverse agonists. Furthermore, target- and pharmacophore-based docking of ligands followed by molecular dynamic simulation experiments resulted in consistent motion of aromatic residues belonging to a network presumably important for activation, thus providing the first structural explanations for the different pharmacological profiles of tested compounds. This study confirms that several referenced so-called antagonists are in fact partial agonists, and because of this undesired activity, we suggest that newly generated molecules should be preferred to efficiently block CCK2R-related physiological effects. Furthermore, data on the structural basis for the different pharmacological features of CCK2R ligands will serve to further clarify CCK2R mechanism of activation.

Received for publication October 18, 2005.

Accepted for publication November 17, 2005.

Address correspondence to: Dr. Daniel Fourmy, IFR 31, Institut Louis Bugnard, BP 84225, Unité 531, 31432 Toulouse cedex 4, France. E-mail: fourmyd{at}toulouse.inserm.fr

This article has been cited by other articles:

				I. Langer, I. G. Tikhonova, C. Boulegue, J.-P. Esteve, S. Vatinel, A. Ferrand, L. Moroder, P. Robberecht, and D. Fourmy Evidence for a Direct and Functional Interaction between the Regulators of G Protein Signaling-2 and Phosphorylated C Terminus of Cholecystokinin-2 Receptor Mol. Pharmacol., March 1, 2009; 75(3): 502 - 513. [Abstract] [Full Text] [PDF]

				C. S. Sum, I. G. Tikhonova, S. Costanzi, and M. C. Gershengorn Two Arginine-Glutamate Ionic Locks Near the Extracellular Surface of FFAR1 Gate Receptor Activation J. Biol. Chem., February 6, 2009; 284(6): 3529 - 3536. [Abstract] [Full Text] [PDF]

				M. Foucaud, E. Marco, C. Escrieut, C. Low, B. Kalindjian, and D. Fourmy Linking Non-peptide Ligand Binding Mode to Activity at the Human Cholecystokinin-2 Receptor J. Biol. Chem., December 19, 2008; 283(51): 35860 - 35868. [Abstract] [Full Text] [PDF]

				E. Marco, M. Foucaud, I. Langer, C. Escrieut, I. G. Tikhonova, and D. Fourmy Mechanism of Activation of a G Protein-coupled Receptor, the Human Cholecystokinin-2 Receptor J. Biol. Chem., September 28, 2007; 282(39): 28779 - 28790. [Abstract] [Full Text] [PDF]